Literature DB >> 23396994

Brain amyloid imaging.

Christopher C Rowe1, Victor L Villemagne.   

Abstract

Imaging of brain β-amyloid plaques with (18)F-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396994     DOI: 10.2967/jnumed.110.076315

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  22 in total

Review 1.  Amyloid positron emission tomography and cognitive reserve.

Authors:  Matteo Bauckneht; Agnese Picco; Flavio Nobili; Silvia Morbelli
Journal:  World J Radiol       Date:  2015-12-28

2.  Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.

Authors:  Tetsuro Tago; Shozo Furumoto; Nobuyuki Okamura; Ryuichi Harada; Hajime Adachi; Yoichi Ishikawa; Kazuhiko Yanai; Ren Iwata; Yukitsuka Kudo
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

3.  Comparison of Three Automated Approaches for Classification of Amyloid-PET Images.

Authors:  Ying-Hwey Nai; Yee-Hsin Tay; Tomotaka Tanaka; Christopher P Chen; Edward G Robins; Anthonin Reilhac
Journal:  Neuroinformatics       Date:  2022-05-27

Review 4.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

5.  A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date.

Authors:  Bern G Lee; MacKenzie J Leavitt; Charles B Bernick; Gabriel C Leger; Gil Rabinovici; Sarah J Banks
Journal:  J Neurotrauma       Date:  2018-06-12       Impact factor: 5.269

6.  The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia.

Authors:  Rik Vandenberghe
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

7.  Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease.

Authors:  Patrizia Giannoni; Florence Gaven; Dimitri de Bundel; Kevin Baranger; Evelyne Marchetti-Gauthier; François S Roman; Emmanuel Valjent; Philippe Marin; Joël Bockaert; Santiago Rivera; Sylvie Claeysen
Journal:  Front Aging Neurosci       Date:  2013-12-24       Impact factor: 5.750

8.  Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes.

Authors:  Masashi Yoshimura; Masahiro Ono; Hiroyuki Watanabe; Hiroyuki Kimura; Hideo Saji
Journal:  Sci Rep       Date:  2014-08-21       Impact factor: 4.379

9.  Targeting Metal-Aβ Aggregates with Bifunctional Radioligand [11C]L2-b and a Fluorine-18 Analogue [18F]FL2-b.

Authors:  Brian P Cary; Allen F Brooks; Maria V Fawaz; Xia Shao; Timothy J Desmond; Garrett M Carpenter; Phillip Sherman; Carole A Quesada; Roger L Albin; Peter J H Scott
Journal:  ACS Med Chem Lett       Date:  2014-11-09       Impact factor: 4.345

10.  In Vivo Amyloid-β Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody.

Authors:  Ann-Marie Waldron; Jens Fissers; Annemie Van Eetveldt; Bianca Van Broeck; Marc Mercken; Darrel J Pemberton; Pieter Van Der Veken; Koen Augustyns; Jurgen Joossens; Sigrid Stroobants; Stefanie Dedeurwaerdere; Leonie Wyffels; Steven Staelens
Journal:  Front Aging Neurosci       Date:  2016-03-31       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.